Related Experiment Video
Updated: Jun 5, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.3K
Personalizing Quality Improvement: Addressing Anticoagulation Gaps in Atrial Fibrillation.
Summary
Many atrial fibrillation patients identified with anticoagulation gaps do not require treatment. A pharmacist-led review confirmed most apparent gaps were explained, highlighting potential overestimation in quality metrics.
Area of Science:
- Pharmacology
- Cardiology
- Health Services Research
Background:
- Atrial fibrillation significantly increases stroke risk.
- Anticoagulation therapy is effective but underutilized in eligible patients, indicating a care quality gap.
- A pharmacist-led quality improvement initiative aimed to address these anticoagulation treatment gaps.
Purpose of the Study:
- To identify, verify, and close apparent anticoagulation treatment gaps in patients with atrial fibrillation.
- To evaluate the accuracy of automated algorithms in detecting anticoagulation care gaps.
Main Methods:
- Adult primary care patients with atrial fibrillation and a CHA2DS2-VASc score of at least 2, without current anticoagulant use, were included.
- Patients were identified using claims and electronic health record data.
- Chart review and provider outreach were used to verify and explain apparent treatment gaps.
Main Results:
- Of 242 patients with apparent gaps, 84% had verified treatment gaps.
- However, 86% of verified gaps were explained by factors like spontaneous AF resolution, patient refusal, procedures, or high bleeding risk.
- Pharmacist review and provider outreach resolved most identified opportunities.
Conclusions:
- Automated algorithms relying solely on claims and EHR data can significantly overestimate anticoagulation care gaps.
- A thorough verification process is crucial for accurate assessment of quality metrics in anticoagulation management.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
01:25Errors occurring during blood pressure monitoring
601
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
601
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
01:16Clot Retraction and Fibrinolysis
4.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.0K